期刊文献+

A Review of the Challenges Associated with the Diagnosis and Therapy of Primary Sclerosing Cholangitis 被引量:3

A Review of the Challenges Associated with the Diagnosis and Therapy of Primary Sclerosing Cholangitis
原文传递
导出
摘要 Primary sclerosing cholangitis (PSC) is a chronic and progressive cholestatic liver disease that often leads to the development of cirrhosis.Complications of PSC include pruritus,fatigue,vitamin deficiencies,metabolic bone disease,dominant biliary strictures,gallstones,and hepatobiliary malignancies,most commonly cholangiocarcinoma (CCA).Despite the presumed autoimmune etiology of PSC,a clear benefit from immunosuppressive agents has not yet been established,and their use is limited by their side effects.Endoscopy is required in evaluation of biliary strictures in PSC to rule out the possibility of CCA.Liver transplantation is currently the only life-extending therapy for patients with end-stage disease.However,disease recurrence can be a source of morbidity and mortality as transplanted patients survive longer.Further studies are needed to develop an optimal therapeutic strategy for patients with PSC to decrease the incidence of complications of the disease,to decrease the need for transplantation,and to extend life expectancy. Primary sclerosing cholangitis (PSC) is a chronic and progressive cholestatic liver disease that often leads to the development of cirrhosis.Complications of PSC include pruritus,fatigue,vitamin deficiencies,metabolic bone disease,dominant biliary strictures,gallstones,and hepatobiliary malignancies,most commonly cholangiocarcinoma (CCA).Despite the presumed autoimmune etiology of PSC,a clear benefit from immunosuppressive agents has not yet been established,and their use is limited by their side effects.Endoscopy is required in evaluation of biliary strictures in PSC to rule out the possibility of CCA.Liver transplantation is currently the only life-extending therapy for patients with end-stage disease.However,disease recurrence can be a source of morbidity and mortality as transplanted patients survive longer.Further studies are needed to develop an optimal therapeutic strategy for patients with PSC to decrease the incidence of complications of the disease,to decrease the need for transplantation,and to extend life expectancy.
机构地区 Department of Medicine
出处 《Journal of Clinical and Translational Hepatology》 SCIE 2014年第1期45-52,共8页 临床与转化肝病杂志(英文版)
关键词 CHOLANGIOCARCINOMA CHOLESTASIS Liver transplantation Primary sclerosing cholangitis Cholangiocarcinoma Cholestasis Liver transplantation Primary sclerosing cholangitis
  • 相关文献

参考文献2

二级参考文献89

  • 1Xiang Lan, Ming-Man Zhang, Cong-Lun Pu, Chun-Bao Guo, Quan Kang, Ying-Chun Li, Xiao-Ke Dai, Yu-Hua Deng, Qiang Xiong, Zhi-Mei Ren.Impact of human leukocyte antigen mismatching on outcomes of liver transplantation:A meta-analysis[J].World Journal of Gastroenterology,2010,16(27):3457-3464. 被引量:3
  • 2[1]Worthington J,Cullen S,Chapman R.lmmunopathogenesis of primary sclerosing cholangitis.Clin Rev Allergy Immunol 2005;28:93-103
  • 3[2]Aadland E,Schrumpf E,Fausa O,Elgjo K,Heilo A,Aakhus T,Gjone E.Primary sclerosing cholangitis:a long-term follow-up study.Scand J Gastroenterol 1987;22:655-664
  • 4[3]Broome U,Bergquist A.Primary sclerosing cholangitis,inflammatory bowel disease,and colon cancer.Semin Liver Dis 2006;26:31-41
  • 5[4]Saarinen S,Olerup O,Broome U.Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis.Am J Gastroenterol 2000;95:3195-3199
  • 6[5]Levy C,Lindor KD.Primary sclerosing cholangitis:epidemiology,natural history,and prognosis.Semin Liver Dis 2006;26:22-30
  • 7[6]Terjung B,Worman HJ.Anti-neutrophil antibodies in primary sclerosing cholangitis.Best Pract Res Clin Gastroenterol 2001;15:629-642
  • 8[7]Terjung B,Spengler U,Sauerbruch T,Worman HJ.& quot;Atypical p-ANCA & quot;in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines.Gastroenterology 2000;119:310-322
  • 9[8]Terjung B,Muennich M,Gottwein J,Soehne J.Identification of myeloid-specific tubulin-beta isotype 5 as target antigen of antineutrophil cytoplasmic antibodies in autoimmune liver disease.Hepatology 2005;42:288A
  • 10[9]Mulder AH,Horst G,Haagsma EB,Limburg PC,Kleibeuker JH,Kallenberg CG.Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases.Hepatology 1993;17:411-417

共引文献14

同被引文献13

引证文献3

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部